Targeted Therapies in Metastatic Colorectal Cancer: An Update

Size: px
Start display at page:

Download "Targeted Therapies in Metastatic Colorectal Cancer: An Update"

Transcription

1 Targeted Therapies in Metastatic Colorectal Cancer: An Update

2 ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab use beyond first progression linked to improvement in survival outcomes Cetuximab in combination with FOLFIRI is an effective first-line therapy Panitumumab is generally well tolerated and has a consistent toxicity profile across studies FOLFIRI = infusional 5-fluorouracil/leucovorin/irinotecan FOLFOX-4 = 5-fluorouracil/leucovorin/oxaliplatin XELOX = capecitabine/oxaliplatin

3 Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer Saltz L, et al. ASCO 2007: Abstract 4028.

4 Background Colorectal cancer is the second leading cause of death from cancer in Canada Approximately 20,800 new cases of colorectal cancer will be diagnosed in 2007 alone 1 Monoclonal antibodies (MAbs) such as bevacizumab, cetuximab, and panitumumab in combination with chemotherapy drugs are showing considerable promise Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that inhibits the vascular endothelial growth factor (VEGF), secreted by tumour cells to bring about new blood vessel formation Cancer Care Ontario guidelines recommend the addition of bevacizumab to improve overall survival As first-line therapy in patients with advanced colorectal cancer receiving 5-fluorouracil (5-FU) based chemotherapy As second-line therapy to patients who did not receive bevacizumab as part of their initial treatment 2 1. Canadian Cancer Statistics, Welch, et al. Cancer Care Ontario, 2005.

5 Background (continued) The NO16966 trial 1 was started as a randomized phase III study to compare the efficacy of XELOX (capecitabine and oxaliplatin) versus FOLFOX-4 (5-fluorouracil, leucovorin, and oxaliplatin) The protocol was amended to include bevacizumab in a partially blinded 2 x 2 factorial design to determine the following objectives: Non-inferiority of XELOX versus FOLFOX-4 Superiority of bevacizumab in combination with chemotherapy (XELOX and FOLFOX-4) versus chemotherapy alone for progression-free survival (PFS). 1. Saltz L, et al. ASCO 2007: Abstract 4028.

6 Study design The study was a double-blind study with regard to bevacizumab and placebo administration Enrolled patient criteria included: ECOG PS 1 Number of unidentified measurable lesions 1 No prior systemic therapy for advanced metastatic colorectal cancer No prior treatment with oxaliplatin or bevacizumab Patients who had undergone prior adjuvant therapy should not have progressed during or within 6 months of completion Saltz L, et al. ASCO 2007: Abstract ECOG = Eastern Cooperative Oncology Group

7 Study design (continued) Saltz L, et al. ASCO 2007: Abstract FOLFOX-4 = 5-fluorouraci/leucovorin/oxaliplatin XELOX = capecitabine/oxaliplatin

8 Study design (continued) Patients randomized to XELOX ± bevacizumab or FOLFOX-4 ± bevacizumab XELOX + bevacizumab or placebo for 21-day cycle Bevacizumab (or placebo) 7.5 mg/kg day 1 Oxaliplatin 130 mg/m 2 day 1 Capecitabine 1,000 mg/m 2 twice daily days 1 14 FOLFOX-4 + bevacizumab or placebo for 14-day cycle Bevacizumab (or placebo) 5 mg/kg day 1 Oxaliplatin 85 mg/m 2 day 1 Folinic acid 200 mg/m 2 days 1, 2 Fluorouracil 400 mg/m 2 bolus days 1, 2 followed by 600 mg/m 2 over 22 h Primary endpoint was progression-free survival Secondary endpoints were overall survival, response rate assessed according to RECIST; safety evaluated using NCI CTC v3.0 Saltz L, et al. ASCO 2007: Abstract NCI CTC= National Cancer Institute Common Toxicity Criteria RECIST = response evaluation criteria in solid tumours

9 Key findings Significant prolongation of progression-free survival (PFS) in the bevacizumab + oxaliplatin based chemotherapy arm (HR = 0.83 [97.5% CI: ]; p = ) Trend toward prolonged overall survival (OS) Higher proportion of discontinuation of therapy because of adverse effects (AEs) that occurred in the bevacizumab-containing arms versus the placebo-containing arms (31% versus 21%) Most treatment discontinuations, however, due to chemotherapy rather than bevacizumab-related events Most common reasons for treatment discontinuation: neurotoxicity, GI events, general disorders, and hematological events Saltz L, et al. ASCO 2007: Abstract 4028.

10 Grade 3 or 4 events with chemotherapy ± bevacizumab Saltz L, et al. ASCO 2007: Abstract 4028.

11 Key conclusions Significant improvement in progression-free survival (PFS) with the addition of bevacizumab to front-line oxaliplatin-based chemotherapy Analysis of on treatment PFS versus general PFS suggests that continuation of bevacizumab until disease progression may be necessary to optimize effect of bevacizumab on PFS Observed overall survival (OS) difference did not reach statistical significance (p = 0.077) Saltz L, et al. ASCO 2007: Abstract 4028.

12 Canadian perspective by Dr. Cripps Equivalence of XELOX to FOLFOX-4 and FOLFOX-6 in both first-line and second-line chemotherapy Infusional lines not needed with XELOX; this is especially relevant for pockets in Canada where infusional pumps not available There are changing toxicities with XELOX versus FOLFOX, but toxicities can be managed easily Recently completed phase I study 1 found response rates of first-line capecitabine (X), irinotecan (I), and oxaliplatin (O) to be very high, overall survival 79%, disease control rate 92; five patients have gone in for surgical resection. XIO well tolerated Targeted therapies are here to stay Level 1 evidence suggests targeted therapy such as bevacizumab can add 4.4 months to progression-free survival Now we need to confirm the efficacy and safety of XIO with and without bevacizumab in a phase II trial 1. Maroun J, et al. ASCO 2007: Abstract FOLFOX-4 = 5-fluorouraci/leucovorin/oxaliplatin FOLFOX-6 = infusional 5-fluorouracil/leucovorin/oxaliplatin XELOX = capecitabine/oxaliplatin

13 Bevacizumab use beyond first progression linked to improvement in survival outcomes Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mcrc): results from a large observational study (BRiTE). Grothey A, et al. ASCO 2007: Abstract

14 Background No data exist regarding Effects of bevacizumab beyond first progression (BBP) Optimal duration of VEGF inhibition, including long-term safety and efficacy of using BBP BRiTE is an observational, non-controlled bevacizumab treatment registry: Initiated in 2004 Evaluates safety and efficacy of bevacizumab in combination with chemotherapy in large, less-selected, community-based population of patients with previously untreated mcrc (metastatic colorectal cancer) Grothey A, et al. ASCO 2007: Abstract BRiTE = Bevacizumab Regimens: Investigation of Treatment Effects and Safety VEGF = vascular endothelial growth factor

15 Study design Patients enrolled from 248 study sites in 49 states between February 2004 and June 2005: Group of 1,953 evaluable patients Metastatic or locally advanced and unresectable colorectal cancer No prior therapy for their metastatic disease Patients with poor ECOG PS also included in the study Investigator decided on Dose, schedule, and duration of bevacizumab Dose, schedule and choice per duration of chemotherapy regimen Primary endpoint: survival beyond first progression Secondary endpoints: time to progression, and overall survival or study termination Grothey A, et al. ASCO 2007: Abstract ECOG PS = Eastern Cooperative Oncology Group performance status

16 Key findings In bevacizumab beyond first progression (BBP) subgroup: Longer survival beyond first progression Longer median overall survival No appreciable difference in bevacizumab-associated safety events between BBP and No BBP subgroups No appreciable increase in incidence of bevacizumab-associated safety events post first progression observed in BBP subgroup: Arterial thromboembolic events Grade 3 or 4 bleeding events GI perforation No apparent increase in incidence of bevacizumab-specific adverse events (AEs) in BBP subgroup Grothey A, et al. ASCO 2007: Abstract 4036.

17 Key conclusions Median overall survival (OS) in BRiTE is 25.1 months, longer than OS previously reported from phase III trial AVF2107 (median OS 20.3 months), despite unselected population Substantially longer median OS and survival beyond first progression in the BBP versus the No BPP subgroups Similar overall rates of bevacizumab-associated safety events prior to first progression or after first progression in the BBP subgroup, compared to patients who received bevacizumab only First report of improvement in survival outcomes associated with BBP for patients who started bevacizumab in first-line setting Grothey A, et al. ASCO 2007: Abstract BBP = bevacizumab beyond first progression BRiTE = Bevacizumab Regimens: Investigation of Treatment Effects andsafety

18 Cetuximab in combination with FOLFIRI is an effective first-line therapy Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mcrc): the CRYSTAL trial Van Cutsem E, et al. ASCO 2007: Abstract 4000.

19 Background The epidermal growth factor receptor (EGFR) belongs to the human epidermal growth factor receptor (HER) family of transmembrane receptors Aberrant cell signalling, mediated through EGFR, plays a pivotal role in tumorigenesis and disease progression Monoclonal antibodies such as cetuximab and panitumumab prevent the binding of the epidermal growth factor and TGF-alpha to the EGFR, and bring about inhibition of cell proliferation 1 Common side effects of anti-egfr therapy include skin toxicities such as acneiform dermatitis, pruritis, erythema, rash, and dry skin 1. McKarney L, et al. New Evidence in Oncology TGF = transforming growth factor

20 Background (continued) Appearance of skin rash may be useful as a surrogate marker of EGFR efficacy Ongoing studies are attempting to elucidate characteristics of target rashes that may correlate with better anti-egfr response CRYSTAL trial initiated to investigate addition of cetuximab to FOLFIRI as first-line treatment EGFR-expressing metastatic colorectal cancer 1 The correlation of severity of skin toxicity with PFS was a secondary endpoint 1. Van Cutsem E, et al. ASCO 2007: Abstract EGFR = epidermal growth factor receptor FOLFIRI = infusional 5-fluorouracil/leucovorin/irinotecan TGF = transforming growth factor

21 Study design Patients (n = 1,217) enrolled from 32 countries had: Histologically confirmed unresectable metastatic colorectal cancer EGFR expression in primary tumour or metastasis as detected by IHC Tumours 1 bi-dimensionally measurable lesion No previous chemotherapy for metastatic disease; adjuvant therapy allowed if stopped minimum 6 months previous (no irinotecan) ECOG PS 2 at study entry Randomized 1:1 to receive either: Group A: cetuximab plus FOLFIRI QW: cetuximab: 400 mg/m 2 initial dose, then 250 mg/m 2 /week Q2W: irinotecan 180 mg/m 2, folinic acid 400 mg/m 2, 5-FU bolus 400 mg/m 2, 5-FU infusion 2,400 mg/m 2 over 46 hours, or Group B: FOLFIRI alone Q2W: irinotecan 180 mg/m 2, folinic acid 400 mg/m 2, 5-FU bolus 400 mg/m 2, 5-FU infusion 2,400 mg/m 2 over 46 hours ECOG = Eastern Cooperative Oncology Group FOLFIRI = infusional 5-fluorouracil/leucovorin/irinotecan Van Cutsem E, et al. ASCO 2007: Abstract IHC = immunohistochemistry

22 Study design (continued) Patient population: Total randomized patients (n = 1,217) Population evaluated for safety (n = 1,202) Intent to treat population (n = 1,198) Primary endpoint: progression-free survival Secondary endpoints: Overall survival Overall response rate (ORR) Disease control rate (DCR) QoL (EORTC QLQ C30) Safety Van Cutsem E, et al. ASCO 2007: Abstract EORTC = European Organisation for Research and Treatment of Cancer QLQ C30 = Quality of Life Questionnaire QoL = quality of life

23 Key findings Progression-free survival (PFS) found to be significantly prolonged with addition of cetuximab to FOLFIRI Subgroup analysis of PFS: Pronounced PFS benefit seen in patients with metastases only to liver More favourable PFS with cetuximab plus FOLFIRI in other subgroups, except for patients with ECOG PS 2 at baseline Significantly longer median PFS for Group A versus Group B (8.9 months and 8 months, respectively, stratified log-rank p-value = ) (Table 1) Van Cutsem E, et al. ASCO 2007: Abstract ECOG PS = Eastern Cooperative Oncology Group performance status FOLFIRI = infusional 5-fluorouracil/leucovorin/irinotecan

24 Progression-free survival Van Cutsem E, et al. ASCO 2007: Abstract 4000.

25 Key findings (continued) Significant increase in response rate with cetuximab (46.9% versus 38.7%, p = ) (Figure 1) Van Cutsem E, et al. ASCO 2007: Abstract 4000.

26 Key findings (continued) Significantly more patients underwent surgery with curative intent (p = ) and had successful resection in cetuximab arm (Figures 2 and 3) Van Cutsem E, et al. ASCO 2007: Abstract 4000.

27 Key findings (continued) Van Cutsem E, et al. ASCO 2007: Abstract FOLFIRI = infusional 5-fluorouracil/leucovorin/irinotecan

28 Safety Treatment generally well tolerated; neutropenia, diarrhea, and skin reactions most common grade 3 or 4 adverse events (Table 2) Van Cutsem E, et al. ASCO 2007: Abstract 4000.

29 Safety (continued) More grade 3 skin reactions associated with cetuximab vs. control Slightly higher incidence of diarrhea Other adverse events, including neutropenia, comparable in groups Better PFS outcomes associated with severity of skin reaction seen in cetuximab-treated patients. Median progression-free survival (PFS): Grade 3 skin reactions: 11.3 months Grade 2 skin reactions: 9.4 months Grade 0 or 1 skin reactions: 5.4 months Van Cutsem E, et al. ASCO 2007: Abstract 4000

30 Key conclusions Significant increase in response rate and progression-free survival in the cetuximab plus FOLFIRI arm Relative risk of progression reduced by approximately 15% in the cetuximab plus FOLFIRI group Treatment-related side effects of cetuximab plus FOLFIRI as expected: moderate occurrence of diarrhea and significantly more frequent skin reactions compared to FOLFIRI alone Van Cutsem E, et al. ASCO 2007: Abstract FOLFIRI = infusional 5-fluorouracil/leucovorin/irinotecan

31 Panitumumab is generally well tolerated and has a consistent toxicity profile across studies Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFR), in patients (pts) with metastatic colorectal cancer (mcrc) across clinical trials Peeters M, et al. ASCO 2007: Abstract 4138.

32 Background Study presented pooled safety data of panitumumab monotherapy from ten phase I to III clinical trials 1 Many studies report clinical activity and tolerability of panitumumab in EGFR-expressing mcrc patients who had progressed during or after completion of chemotherapy with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens Panitumumab: Recombinant fully human IgG2 MAb Binds specifically to the EGFR Competitively inhibits the binding of ligands to receptor 1. Peeters M, et al. ASCO 2007: Abstract EGFR= epidermal growth factor receptor IgG = immunoglobulin G MAb = monoclonal antibody mcrc = metastatic colorectal cancer

33 Study design Pooled safety data from ten clinical studies (n = 966) of panitumumab monotherapy in patients with mcrc Patients with mcrc and ECOG PS 0-2 included in study (one patient ECOG PS 3) Primary endpoints: clinical safety events including Incidence of adverse events, including skin-related toxicity and infusion reactions Deaths Drug exposure Incidence of dose changes Immunogenicity of panitumumab Secondary endpoints: changes in metabolic and laboratory assessments after panitumumab infusions Peeters M, et al. ASCO 2007: Abstract ECOG PS = Eastern Cooperative Oncology Group performance status mcrc = metastatic colorectal cancer

34 Study design (continued) Panitumumab administered by infusion over 30 to 60 minutes per protocol; premedication not required. Dosing schedule shown in Table 1 Peeters M, et al. ASCO 2007: Abstract 4138.

35 Key findings Safety results summarized in Tables 2, 3, and 4 Peeters M, et al. ASCO 2007: Abstract Fifteen percent of patients (149) died during the study (including deaths within 30 days of last dose of panitumumab). Two deaths considered to be treatment related: Pulmonary edema in patient with history of hypercoagulation, deep vein thrombosis, peripheral vascular disease, and diabetes mellitus Myocardial infarction and cerebrovascular accident observed in patient with history of anemia, diabetes mellitus, deep vein thrombosis, hyperlipidemia, hypertension, and supraventricular tachycardia Antibodies to panitumumab: patients who were predose negative and had persistent postdose positive results: ELISA found 2/778 patients (0.3%) tested positive for anti-panitumumab antibodies Biacore found 2/638 patients (0.4%) tested positive for anti-panitumumab antibodies Bioassay determined 6/638 patients (1%) had neutralizing antibodies to panitumumab

36 Incidence of skin-related toxicity Peeters M, et al. ASCO 2007: Abstract 4138.

37 Adverse events excluding skin-related toxicity Peeters M, et al. ASCO 2007: Abstract 4138.

38 Infusion reactions reported per investigator Peeters M, et al. ASCO 2007: Abstract 4138.

39 Key conclusions Panitumumab generally well tolerated with consistent toxicity profile across studies Common toxicities included fatigue, gastrointestinal side effects, and skin-related (majority were grade 1 or 2) Grade 3 or 4 infusion reactions rare (0.4% of patients); no premedication required Treatment-related adverse events of grade 3 or 4 reported in 20% patients Four percent of patients permanently discontinued panitumumab or withdrew from study due to treatment-related adverse events Anti-panitumumab antibody formation postdose was detected in <1% of patients by ELISA and Biacore Incidence of skin-related adverse events in Figure 1 Peeters M, et al. ASCO 2007: Abstract 4138.

40 Figure 1 : Any skin-related adverse events Peeters M, et al. ASCO 2007: Abstract 4138.

Tumors in the Randomized German AIO study KRK-0306

Tumors in the Randomized German AIO study KRK-0306 FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German

More information

Incorporating biologics in the management of older patients with metastatic colorectal cancer

Incorporating biologics in the management of older patients with metastatic colorectal cancer Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014

More information

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,

More information

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc

MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR

More information

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000

More information

OVERALL CLINICAL BENEFIT

OVERALL CLINICAL BENEFIT cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,

More information

Chemotherapy of colon cancers

Chemotherapy of colon cancers Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Does it matter which chemotherapy regimen you partner with the biologic agents?

Does it matter which chemotherapy regimen you partner with the biologic agents? Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Aflibercept (Zaltrap) for Metastatic Colorectal Cancer September 5, 2014

pan-canadian Oncology Drug Review Final Clinical Guidance Report Aflibercept (Zaltrap) for Metastatic Colorectal Cancer September 5, 2014 pan-canadian Oncology Drug Review Final Clinical Guidance Report Aflibercept (Zaltrap) for Metastatic Colorectal Cancer September 5, 2014 DISCLAIMER Not a Substitute for Professional Advice This report

More information

Opinion 17 October 2012

Opinion 17 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 October 2012 VECTIBIX 20 mg/ml, concentrate for solution for infusion B/1 vial of 5 ml (CIP code: 3400957181857)

More information

Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?

Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old

More information

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of

More information

DALLA CAPECITABINA AL TAS 102

DALLA CAPECITABINA AL TAS 102 DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu

More information

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause. CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase

More information

DOSING AND INFORMATION GUIDE LEAPS AHEAD

DOSING AND INFORMATION GUIDE LEAPS AHEAD DOSING AND INFORMATION GUIDE In patients with WT RAS* mcrc 1 VECTIBIX (panitumumab) LEAPS AHEAD 5.6-month increase in median OS with FOLFOX vs FOLFOX alone 1 Spot the difference. CHOOSE VECTIBIX PRIME

More information

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev

More information

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate

More information

What s New in Colon Cancer? Therapy over the last decade

What s New in Colon Cancer? Therapy over the last decade What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-

More information

Κίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών

Κίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary

More information

MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra

MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Cetuximab (Erbitux) for Metastatic Colorectal Cancer January 10, 2014

pan-canadian Oncology Drug Review Final Clinical Guidance Report Cetuximab (Erbitux) for Metastatic Colorectal Cancer January 10, 2014 pan-canadian Oncology Drug Review Final Clinical Guidance Report Cetuximab (Erbitux) for Metastatic Colorectal Cancer January 10, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is

More information

Tobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1

Tobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1 Botrel et al. BMC Cancer (2016) 16:677 DOI 10.1186/s12885-016-2734-y RESEARCH ARTICLE Open Access Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated

More information

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of

More information

What s New? Dr. Barbara Melosky

What s New? Dr. Barbara Melosky Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment

More information

What to do after 1 st line failure?

What to do after 1 st line failure? ESMO Preceptorship Programme Colorectal Cancer Singapore 20-22 nd 2016 JY Douillard MD PhD ESMO CMO What to do after 1 st line failure? mcrc: How to maximize survival? Improving 1st line therapy efficacy

More information

Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos?

Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Prof. Dr. Paulo M. Hoff Instituto do Câncer do Estado de São Paulo - ICESP Faculdade de Medicina Universidade de São Paulo (USP) Conflicts

More information

Colon Cancer Molecular Target Agents

Colon Cancer Molecular Target Agents Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester

More information

RAS and BRAF in metastatic colorectal cancer management

RAS and BRAF in metastatic colorectal cancer management Review Article RAS and BRAF in metastatic colorectal cancer management Jun Gong 1, May Cho 1, Marwan Fakih 2 1 Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA; 2 Medical

More information

Panitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd

Panitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed

More information

Bevacizumab is currently licensed for the following indication relevant for this NICE review:

Bevacizumab is currently licensed for the following indication relevant for this NICE review: Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both

More information

Panel Two: Evidence for Use of Maintenance Therapy

Panel Two: Evidence for Use of Maintenance Therapy Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued

More information

Chemotherapy options and outcomes in older adult patients with colorectal cancer

Chemotherapy options and outcomes in older adult patients with colorectal cancer Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School

More information

MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015

MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015 Supported by an Independent Educa1onal Grant from MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015 BY DR. GUILLEM ARGILES, BARCELONA, SPAIN Cancers of the Lower GI Tract RAISE: A RANDOMIZED, DOUBLE-BLIND,

More information

First line treatment in metastatic colorectal cancer

First line treatment in metastatic colorectal cancer First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was

More information

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015

pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended

More information

Advances in Chemotherapy of Colorectal Cancer

Advances in Chemotherapy of Colorectal Cancer Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre

More information

Cetuximab for the first-line treatment of metastatic colorectal cancer

Cetuximab for the first-line treatment of metastatic colorectal cancer Cetuximab for the first-line treatment of metastatic colorectal cancer Issued: August 2009 guidance.nice.org.uk/ta176 NICE has accredited the process used by the Centre for Health Technology Evaluation

More information

A Single-Center Phase 2 Trial. Bevacizumab is a humanized immunoglobulin G1 murine antibody directed against all isoforms of

A Single-Center Phase 2 Trial. Bevacizumab is a humanized immunoglobulin G1 murine antibody directed against all isoforms of Bevacizumab in Association With de Gramont 5-Fluorouracil/Folinic Acid in Patients With Oxaliplatin-, Irinotecan-, and Cetuximab-Refractory Colorectal Cancer A Single-Center Phase 2 Trial Bruno Vincenzi,

More information

Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta242

Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta242 Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first- line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination

More information

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

More information

Chemotherapy for Advanced Gastric Cancer

Chemotherapy for Advanced Gastric Cancer Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,

More information

COMETS: COlorectal MEtastatic Two Sequences

COMETS: COlorectal MEtastatic Two Sequences COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed

More information

Association of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients

Association of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients Colorectal Cancer Association of Canada Learning about Colorectal Cancer A Personalized Treatment Guide for Patients Avastin is a trademark of Genentech, Inc., Used under licence. Camptosar is a registered

More information

ASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.

ASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D. ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the

More information

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal

More information

Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms

Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms 21. Ärzte Fortbildungskurs in Klinischer Onkologie 24.-26. Februar 2011 Kantonspital St. Gallen / Schweiz Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms Claus-Henning Köhne Klinik

More information

Overview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013

Overview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally

More information

Avastin NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. bevacizumab (rch)

Avastin NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. bevacizumab (rch) NAME OF THE MEDICINE Avastin bevacizumab (rch) CAS 216974-75-3 Bevacizumab is an immunoglobulin G (IgG) composed of two identical light chains, consisting of 214 amino acid residues and two 453 residue

More information

trial update clinical

trial update clinical clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must

More information

4. Aflibercept showed significant improvement in overall survival (OS), the primary

4. Aflibercept showed significant improvement in overall survival (OS), the primary Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin

More information

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical

More information

Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS

Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver

More information

OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER

OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER & OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina

More information

Q11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER?

Q11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER? Q11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER? Version 11/24/2011 3:08 PM Q11 TABLE OF CONTENTS SCIENTIFIC REPORT... 6 1 INTRODUCTION... 6 1.1 PICO...

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

The 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract

The 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against

More information

Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases

Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Case Reports in Oncological Medicine, Article ID 790192, 4 pages http://dx.doi.org/10.1155/2014/790192 Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Muhammad

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE MERCK SERONO LTD. SINGLE TECHNOLOGY APPRAISAL SUBMISSION: ERBITUX (CETUXIMAB) FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER. - 1 - Contents

More information

Adjuvant treatment Colon Cancer

Adjuvant treatment Colon Cancer ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant

More information

Cancer Cell Research 14 (2017)

Cancer Cell Research 14 (2017) Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of

More information

Adjuvant/neoadjuvant systemic treatment of colorectal cancer

Adjuvant/neoadjuvant systemic treatment of colorectal cancer 5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico

More information

Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)

Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University

More information

METRIC Study Key Eligibility Criteria

METRIC Study Key Eligibility Criteria The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).

More information

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,

More information

OWa 22 80) :IEZ

OWa 22 80) :IEZ Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab

More information

Università degli Studi di Pisa Facoltà di Medicina e Chirurgia Scuola di Specializzazione in Oncologia

Università degli Studi di Pisa Facoltà di Medicina e Chirurgia Scuola di Specializzazione in Oncologia Università degli Studi di Pisa Facoltà di Medicina e Chirurgia Scuola di Specializzazione in Oncologia Tesi di Specializzazione EZH2 polymorphisms and outcome of metastatic colorectal cancer patients Candidato:

More information

Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Panitumumab (Vectibix ) RUTHANN M. GIUSTI, KAUSHIKKUMAR A. SHASTRI, MARTIN H. COHEN, PATRICIA KEEGAN, RICHARD PAZDUR Office of Oncology

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

More information

1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)

1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) 1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of

More information

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug

More information

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014

More information

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant

More information

Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience

Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience JBUON 2016; 21(1): 70-79 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cetuximab in third-line therapy of patients with metastatic colorectal

More information

Toxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -

Toxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools - Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -

More information

ADJUVANT CHEMOTHERAPY...

ADJUVANT CHEMOTHERAPY... Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED

More information

4.3 Input parameters Patient

4.3 Input parameters Patient Table of Content 1 Introduction -------------------------------------------------------------------------------------------------- 7 Summary -----------------------------------------------------------------------------------------------------------

More information

Vectibix. Vectibix (panitumumab) Description

Vectibix. Vectibix (panitumumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix

More information

Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer JBUON 2017; 22(4): 863-868 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line

More information

OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER

OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.

More information

Targeting colorectal cancer with human anti-egfr monoclonocal antibodies: focus on panitumumab

Targeting colorectal cancer with human anti-egfr monoclonocal antibodies: focus on panitumumab REVIEW Targeting colorectal cancer with human anti-egfr monoclonocal antibodies: focus on panitumumab George P Kim Axel Grothey College of Medicine, Mayo Clinic Abstract: The human anti-epidermal growth

More information

The treatment of metastatic colorectal cancer in 2007

The treatment of metastatic colorectal cancer in 2007 The treatment of metastatic colorectal cancer in 2007 Prof Eric Van Cutsem, MD, PhD Gastrointestinal Oncology Unit University Hospital Gasthuisberg Leuven - Belgium CRC is a major health concern Life-time

More information

Medical Therapy of Colorectal Cancer in the Biomarker Era

Medical Therapy of Colorectal Cancer in the Biomarker Era Medical Therapy of Colorectal Cancer in the Biomarker Era Axel Grothey Professor of Oncology Mayo Clinic College of Medicine Rochester, Minnesota Disclosures Consulting activities (honoraria went to the

More information

ADVANCES IN COLON CANCER

ADVANCES IN COLON CANCER ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI

More information

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Regorafenib (Stivarga) for Metastatic Colorectal Cancer November 15, 2013

pan-canadian Oncology Drug Review Final Clinical Guidance Report Regorafenib (Stivarga) for Metastatic Colorectal Cancer November 15, 2013 pan-canadian Oncology Drug Review Final Clinical Guidance Report Regorafenib (Stivarga) for Metastatic Colorectal Cancer November 15, 2013 DISCLAIMER Not a Substitute for Professional Advice This report

More information

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

Gastric cancer and lung cancer impose a substantial

Gastric cancer and lung cancer impose a substantial Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non Small-Cell Lung Cancer By Loretta Fala, Medical Writer Gastric cancer and lung cancer impose a substantial

More information

Horizon Scanning in Oncology

Horizon Scanning in Oncology Horizon Scanning in Oncology Panitumumab (Vectibix ) for the first-line treatment of metastatic colorectal cancer DSD: Horizon Scanning in Oncology Nr. 011 ISSN online 2076-5940 Horizon Scanning in Oncology

More information

OHTAC Recommendation. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer

OHTAC Recommendation. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer OHTAC Recommendation KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer Presented to the Ontario Health Technology Advisory Committee in August, 2010 December 2010 Issue Background In February

More information

Objectives. Briefly summarize the current state of colorectal cancer

Objectives. Briefly summarize the current state of colorectal cancer Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard

More information

Fighting a Smarter War On Colon Cancer:

Fighting a Smarter War On Colon Cancer: Fighting a Smarter War On Colon Cancer: Value as a new endpoint? John L. Marshall, MD Tel: (202) 444-0275 Fax: (202) 444-1229 http://lombardi.georgetown.edu/gi Stakeholder Motivation Stakeholders FDA CMS/Payers

More information